StreetInsider.com News Articles

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 08:00:00 -0400

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on June 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 08:00:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 08:00:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 08:00:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common

Wedbush Starts Damora Therapeutics (DMRA) at Outperform

Thu, 28 May 2026 06:53:54 -0400

Wedbush analyst David Nierengarten initiates coverage on Damora Therapeutics (NASDAQ: DMRA) with a Outperform rating and a price target of $35.00.

For an analyst ratings summary and ratings history on Damora Therapeutics click here. For more ratings news on Damora Therapeutics click here.

Shares of Damora Therapeutics closed at $25.21 yesterday.

Form SCHEDULE 13G/A Damora Therapeutics, Filed by: Point72 Asset Management, L.P.

Fri, 15 May 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260515/26506235.html

Form SCHEDULE 13G/A Damora Therapeutics, Filed by: Point72 Asset Management, L.P.

Fri, 15 May 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260515/26506235.html

Form SCHEDULE 13G/A Damora Therapeutics, Filed by: Jain Global LLC

Fri, 15 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260515/26506005.html

Form SCHEDULE 13G/A Damora Therapeutics, Filed by: Jain Global LLC

Fri, 15 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260515/26506005.html

Form SCHEDULE 13G Damora Therapeutics, Filed by: Avoro Capital Advisors LLC

Fri, 15 May 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260515/26499946.html

Form SCHEDULE 13G Damora Therapeutics, Filed by: Avoro Capital Advisors LLC

Fri, 15 May 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260515/26499946.html

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected